Nusinersen treatment of spinal muscular atrophy - a systematic review.
CONCLUSIONS: Nusinersen increased survival without permanent ventilatory support in children with SMA type 1. Improvements in SMA type 2 and 3 were less evident. Better outcomes were seen in young children with a short disease duration, particularly in children receiving nusinersen before symptom onset. Newborn SMA screening may facilitate presymptomatic treatment with splice modification (nusinersen, risdiplam) or gene implantation therapy (AVXS-101, zolgensma).
PMID: 32800069 [PubMed - in process]
Source: Danish Medical Journal - Category: General Medicine Tags: Dan Med J Source Type: research
More News: Brain | Child Development | Children | Denmark Health | General Medicine | Genetics | Lumbar Puncture | Motor Neurone Disease | Neurology | Respiratory Medicine | Spinal Muscular Atrophy | Study